Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 6:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 453 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Motor Neuron Disease, Amyotrophic Lateral Sclerosis Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Examining Interactions Between PALS and Caregivers

NCT06819124
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Structured Communicative Interaction, Unstructured communicative interaction
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 90 Years
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 14, 2026, 6:42 PM EDT
Completed Phase 1Phase 2 Interventional

Supported Treadmill Ambulation Training (STAT) for Patients Diagnosed With Amyotrophic Lateral Aclerosis

NCT00956488
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Lou Gehrig's Disease
Interventions
Treadmill Exercise
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
25 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 14, 2026, 6:42 PM EDT
Completed Phase 2Phase 3 Interventional Results available

HEALEY ALS Platform Trial - Regimen A Zilucoplan

NCT04436497
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Zilucoplan, Matching Placebo
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 14, 2026, 6:42 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

HEALEY ALS Platform Trial - Master Protocol

NCT04297683
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Zilucoplan, Verdiperstat, CNM-Au8, Pridopidine, SLS-005 Trehalose, ABBV-CLS-7262, DNL343, NUZ-001
Drug
Lead sponsor
Merit E. Cudkowicz, MD
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
81
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 66 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 14, 2026, 6:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis

NCT02039401
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
VM202
Biological
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
21 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 14, 2026, 6:42 PM EDT
Terminated Phase 2 Interventional Results available

MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)

NCT04579666
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Interventions
Pegcetacoplan (APL-2), Placebo
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Los Angeles, California • Aurora, Colorado • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 14, 2026, 6:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance Myography

NCT01803386
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
EIM Measurements
Device
Lead sponsor
Skulpt, Inc.
Industry
Eligibility
21 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2015 · Synced Oct 14, 2026, 6:42 PM EDT
Completed No phase listed Observational

PRISM Registry: Pseudobulbar Affect Registry Series

NCT01366027
View directory record Official record
Conditions
Alzheimer's Disease, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), Parkinson's Disease, Stroke, Traumatic Brain Injury
Interventions
Not listed
Lead sponsor
Avanir Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5,290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Aliso Viejo, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Oct 14, 2026, 6:42 PM EDT
Terminated Phase 2 Interventional Results available

Study of Safety and Proof of the Mechanism of BLZ945 in ALS Patients

NCT04066244
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
BLZ945
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
New Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 14, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Evaluation of NDV-3A Vaccine in Preventing S. Aureus Colonization

NCT03455309
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
NDV-3A, Placebo
Biological
Lead sponsor
NovaDigm Therapeutics, Inc.
Industry
Eligibility
17 Years to 35 Years · Male only
Enrollment
382 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Fort Benning, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 29, 2020 · Synced Oct 14, 2026, 6:42 PM EDT
Completed Early Phase 1 Interventional

SSRIs vs. TCAs for Depression in ALS Patients

NCT02851914
View directory record Official record
Conditions
Depression, Amyotrophic Lateral Sclerosis
Interventions
Tricyclic Antidepressants ("TCA"), Selective Serotonin Uptake Inhibitors ("SSRI")
Drug
Lead sponsor
St. Louis University
Other
Eligibility
25 Years to 80 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 14, 2026, 6:42 PM EDT
Recruiting Not applicable Interventional

Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study

NCT06649955
View directory record Official record
Conditions
ALS - Amyotrophic Lateral Sclerosis
Interventions
Multi-site direct current stimulation (DCS)
Device
Lead sponsor
PathMaker Neurosystems Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 14, 2026, 6:42 PM EDT
Terminated No phase listed Observational

Neurogenic Dysphonia/Dysphagia Registry

NCT02493491
View directory record Official record
Conditions
Neurogenic Dysphonia, Neurogenic Dysphagia
Interventions
Not listed
Lead sponsor
Merz North America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
12
States / cities
La Jolla, California • Sacramento, California • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2016 · Synced Oct 14, 2026, 6:42 PM EDT
Terminated Not applicable Interventional

Polysomnography-directed Noninvasive Ventilation in Amyotrophic Lateral Sclerosis (ALS)

NCT01363882
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
Sleep study-guided adjustment of NIV, Standard initiation of NIV
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 13, 2020 · Synced Oct 14, 2026, 6:42 PM EDT
Completed Phase 1 Interventional Results available

A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS)

NCT02525471
View directory record Official record
Conditions
ALS
Interventions
RNS60
Drug
Lead sponsor
Sabrina Paganoni, M.D.
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 28, 2021 · Synced Oct 14, 2026, 6:42 PM EDT
Completed No phase listed Observational

Amyotrophic Lateral Sclerosis Web Based Patient Care Database: ALSConnection.Org

NCT00302198
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
ALS Registry
Behavioral
Lead sponsor
Forbes Norris MDA/ALS Research Center
Other
Eligibility
Not listed
Enrollment
15,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 14, 2026, 6:42 PM EDT
Completed No phase listed Observational

COVID-19 Amyotrophic Lateral Sclerosis (ALS) Registry

NCT04559009
View directory record Official record
Conditions
Covid19, Amyotrophic Lateral Sclerosis
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 14, 2026, 6:42 PM EDT
Completed No phase listed Observational

Validation of a New Device to Measure Neuromuscular Disease Progression

NCT00606918
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis & Other Neuromuscular Disorders
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2011 · Synced Oct 14, 2026, 6:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS)

NCT00677768
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease, Primary Lateral Sclerosis, Nervous System Diseases, Hereditary Spastic Paraparesis
Interventions
No intervention
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years to 80 Years
Enrollment
475 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
29
States / cities
Phoenix, Arizona • Orange, California • Jacksonville, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2016 · Synced Oct 14, 2026, 6:42 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Cervical Spinal Cord Metabolism and Microstructure in Amyotrophic Lateral Sclerosis(ALS)

NCT02000713
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
MRI, Clinical Exam
Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 14, 2026, 6:42 PM EDT
Completed Phase 2 Interventional Results available

Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)

NCT02460679
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
EPI-589
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
21 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 14, 2026, 6:42 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Retinal Imaging in Neurodegenerative Disease

NCT03233646
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, Multiple Sclerosis, Huntington Disease, Lewy Body Dementia, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis (ALS), APOE-4 Positive, Traumatic Brain Injury, Concussion, Post-Traumatic Stress Disorder, Down Syndrome, Neuro-Degenerative Disease, Normal Cognition
Interventions
Retinal and Choroidal Imaging
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 14, 2026, 6:42 PM EDT
Completed Phase 2 Interventional

Study of ANX005 in Adults With Amyotrophic Lateral Sclerosis (ALS)

NCT04569435
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
ANX005
Drug
Lead sponsor
Annexon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Phoenix, Arizona • Orange, California • Gainesville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Oct 14, 2026, 6:42 PM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Personalized Antisense Oligonucleotide Therapy for a Participant With TARDBP ALS

NCT07703462
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
nL-TARDB-002
Drug
Lead sponsor
n-Lorem Foundation
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 14, 2026, 6:42 PM EDT